MET and melanoma: Considering that most WTBRAF melanoma tumors show alterations in c-Met expression with at least 24% of receptor amplification, it can be reasonably speculated that a common subset of melanoma patients can be selected for the triple combination although adverse events may be an issue, and would have to be carefully monitored.